• Evaluating the Benefits and Risks of Weight Loss Drugs

    Bio-IT World| Weight loss medications are in “skyrocketing” utilization. Yet there have been no comprehensive investigations or studies on the effectiveness and risks of glucagon-like peptide-1 receptor agents (GLP-1RA). Researchers at the WashU Medicine collaborated with the Veterans Affairs (VA) St. Louis Health Care System to examine and evaluate more than two million people with diabetes taking popular weight loss drugs such as Ozempic.

    Apr 3, 2025
  • Large Genetic Study Further Untangles the Height-Health Connection

    Bio-IT World| In the largest phenome wide association study across diverse population groups, an international team of researchers have identified 254 statistically significant associations between genetically explained height and various diseases. Genetically predicted height was linked with decreased risk of 90 diseases and increased risk of 164 others, most notably atrial fibrillation, and a series of conditions involving mental health and the endocrine system that have not been previously described.

    Apr 2, 2025
  • Bio-IT World Best of Show Finalists Named

    Bio-IT World| Finalists have been named for the 2025 Bio-IT World Best of Show Awards program. More than 20 new products will be on display next week at the Bio-IT World Conference & Expo. New products will be on display from Artificial, Boulder BioComputing, Copyright Clearance Center, Chemspace, Dantech Corporation, Discngine, expert.ai, Genomenon, Globus, GRAU DATA, iuvo, Komprise, Orchestra Bio, Quantum Corporation, QuartzBio, Sinequa, Tech Mahindra, TetraScience, The Hyve, and Velsera.

    Mar 28, 2025
  • Pistoia Alliance Reducing Carbon Footprint, Thermo Fisher Next-Gen Hybrid Capture Assay, More

    Bio-IT World| The Pistoia Alliance launched the next phase of its project to measure and reduce the carbon footprint of clinical trials; the Lupus Research Alliance announced the inaugural recipients of the new Targeted Research Program on Engineered Cell Therapies for Lupus; and more.

    Mar 27, 2025
  • Follow the Money: Gene Editing Therapeutics, Breast Cancer AI Predictive Platform, More

    Bio-IT World| Arbor Biotechnologies will advance its pipeline of novel gene editing therapeutics targeting diseases in the liver and central nervous system; Ataraxis AI will further the development of Ataraxis Breast, the world’s first AI-native prognostic/predictive platform for breast cancer; and more.

    Mar 26, 2025